Clinical research progress of ridaforolimus (AP23573, MK8668) over the past decade: a systemic review

• Principais autores: Lumin Wang (Autor), Qining Qiu (Autor), Dawei Yang (Autor), Chang Cao (Autor), Yanqin Lu (Autor), Yulan Zeng (Autor), Weiwen Jiang (Autor), Yun Shen (Autor), Yanrong Ye (Autor)
• Formato: Livro
• Publicado em: Frontiers Media S.A., 2024-03-01T00:00:00Z.
• Assuntos: article
• Acesso em linha: Connect to this object online.

Rapamycin, an established mTOR inhibitor in clinical practice, is widely recognized for its therapeutic efficacy. Ridaforolimus, a non-prodrug rapalog, offers improved aqueous solubility, stability, and affinity compared to rapamycin. In recent years, there has been a surge in clinical trials involv...